<DOC>
	<DOCNO>NCT01999764</DOCNO>
	<brief_summary>This Phase IIa proof-of-concept study evaluate effect oral QLT091001 adult impair dark adaptation .</brief_summary>
	<brief_title>Evaluation Effects Oral QLT091001 Adults With Impaired Dark Adaptation</brief_title>
	<detailed_description>This proof-of-concept study randomize , parallel design two different oral dos QLT091001 compare placebo evaluate treatment effect patient impaired dark adaptation . Approximately 40 subject enrol study approximately 7 center US .</detailed_description>
	<mesh_term>Retinol acetate</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<criteria>Male female subject â‰¥60 yrs early agerelated macular degeneration ( AMD ) base LLLC BCVA criterion evidence impair dark adaptation Subjects high luminance high contrast bestcorrected visual acuity ( HLHC BCVA ) 40 letter ( 20/40 Snellen ) good study eye Capable willing provide consent Women child bear potential Subjects late AMD optic neuropathy study eye Subjects posterior subcapsular cataract multifocal intraocular lens ( IOL ) study eye Subjects actively participate experimental therapy study receive experimental therapy within 60 day Day 0 take prescription/investigational oral retinoid medication within 6 month Day 0 Subjects take agerelated eye disease study ( AREDS ) supplement contain betacarotene</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>